Busulfan–fludarabine‐ or treosulfan–fludarabine‐based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19122 ↗Kurz gefasst
Leserbrief in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Annamária Cseh und 19 weiteren Autor:innen. Beteiligte Einrichtung: St. Anna Children's Cancer Research Institute, Vienna, Austria. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Anemia, Sickle Cell. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: St. Anna Children's Cancer Research Institute.
Abstract (Originalsprache)
How important is choice of conditioning regimen in allogeneic haematopoietic stem cell transplantation (HSCT) for sickle cell disease (SCD)? We compared HSCT outcomes by conditioning regimen in paediatric patients with SCD from the EBMT registry. In 2010-2020, 251 patients aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- St. Anna Children's Cancer Research Institute, Vienna, Austria.
- European Society for Blood and Marrow Transplantation (EBMT) Statistical Unit, Paris, France.
- Imperial College Healthcare NHS Trust, St Mary's Hospital, London, England.
- Fondazione IME Policlinico Tor Vergata Rome, Rome, Italy.
- Pediatric Hematology, Oncology and Stem Cell Transplant Division, Padua University and Hospital, Padova, Italy.
- Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany.
ORCID-Profile: Marco Zecca, Franco Locatelli, Marianne Ifversen, Robert Wynn, Selim Corbacioglu, Christina Peters
Förderung
- St. Anna Children's Cancer Research Institute
Zitieren
APA
Cseh, A., Galimard, J. E., de la Fuente, J., Isgro, A., Zecca, M., Garwer, B., Biffi, A., Aljurf, M., Sundin, M., Belendez, C., Locatelli, F., Balduzzi, A., Lawson, S., Sengeloev, H., Ifversen, M., Saccardi, R., Wynn, R., Lankester, A. C., Corbacioglu, S., & Peters, C. (2024). Busulfan–fludarabine‐ or treosulfan–fludarabine‐based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties. British Journal of Haematology. https://doi.org/10.1111/bjh.19122
Vancouver
Cseh A, Galimard JE, de la Fuente J, Isgro A, Zecca M, Garwer B, et al. Busulfan–fludarabine‐ or treosulfan–fludarabine‐based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties. British Journal of Haematology. 2024. doi:10.1111/bjh.19122
BibTeX
@article{Cseh2024,
author = {Cseh, Annamária and Galimard, Jacques-Emmanuel and de la Fuente, Josu and Isgro, Antonella and Zecca, Marco and Garwer, Birgit and Biffi, Alexandra and Aljurf, Mahmoud and Sundin, Mikael and Belendez, Cristina and Locatelli, Franco and Balduzzi, Adriana and Lawson, Sarah and Sengeloev, Henrik and Ifversen, Marianne and Saccardi, Riccardo and Wynn, Robert and Lankester, Arjan C and Corbacioglu, Selim and Peters, Christina},
title = {Busulfan–fludarabine‐ or treosulfan–fludarabine‐based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19122}
}
EUVIMED